Key result
Maintenance treatment with subcutaneous immunoglobulin at 0.2 g/kg or 0.4 g/kg weekly significantly reduced CIDP relapse or withdrawal compared to placebo (39% and 33% vs 63%; p=0.0007).
Why the study?
Does subcutaneous immunoglobulin reduce CIDP relapse or withdrawal in adults with CIDP responding to intravenous immunoglobulin?
Population
172 adults with definite or probable chronic inflammatory demyelinating polyneuropathy who responded to…
Comparison
Subcutaneous immunoglobulin 20% solution weekly… vs Placebo weekly for 24 weeks.
Design
RCT, 1:1:1 ratio with an interactive voice and web response system with a…
Follow-up
24 weeks
Authors
Loading...
Supports subcutaneous immunoglobulin maintenance in CIDP; confirms reduced relapse versus placebo in IVIG responders.
RCT (n=172)
Double-blind
1:1:1 ratio with an interactive voice and web response system with a block size of six, stratified by region
Yes
Does subcutaneous immunoglobulin reduce CIDP relapse or withdrawal in adults with CIDP responding to intravenous immunoglobulin?
Absolute Risk Reduction: 25 (95% CI 6–41)
Absolute Event Rate: 39% vs 63%
Absolute Risk Reduction: 25%
p-value: p=0.007
Subcutaneous immunoglobulin at both 0.2 g/kg and 0.4 g/kg weekly is efficacious and well-tolerated as maintenance treatment for CIDP, significantly reducing relapse or withdrawal compared to placebo.
Schaik et al. (2017) conducted an RCT in Chronic inflammatory demyelinating polyneuropathy (CIDP) (n=172). Subcutaneous immunoglobulin (SCIg) IgPro20 vs. Placebo (2% human albumin solution) was evaluated on Proportion of patients with a CIDP relapse or who were withdrawn for any other reason during 24 weeks of treatment (ARR 25%, 95% CI 6-41, p=0.007). Maintenance treatment with subcutaneous immunoglobulin at 0.2 g/kg or 0.4 g/kg weekly significantly reduced CIDP relapse or withdrawal compared to placebo (39% and 33% vs 63%; p=0.0007).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: